IPO Date: Dec 20 to Dec 24 2024
Listing Date: Dec 30 2024
1.Investment in one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility.
2.Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company.
3.Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary.
4.Funding the working capital requirements of our Company.
5.Investment in our Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements.
6.Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
1101 To 1103, 11th Floor, South Tower One 42 Opp. Jayantilal Park Ambali Bopal Road
Ahmedabad
Gujarat
380054
079-29999857
info@senorespharma.com
www.senorespharma.com
MUFG Intime India Pvt Ltd.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Senores Pharmaceuticals has informed that it enclosed a copy of Media Release being issued by the Company on ‘Senores Pharmaceuticals, Inc. announces Strategic Joint Venture in the United States, positioning the group for U.S. Federal and Defense Sector Supplies’. The same is also being uploaded on the website of the Company at www.senorespharma.com.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, Senores Pharmaceuticals has informed that the officials of the Company will be meeting Analysts/ Investors at its Corporate Office situated in Ahmedabad, Gujarat as per the details enclosed. Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Spencer’s Retail has informed that the Q4FY26 results conference call through a group meet, with the investors and analysts is scheduled to be held on Friday, May 22, 2026 at 11:00 am (IST). This information is available on the website of the Company at www.spencersretail.com. The company has enclosed an invite for the same.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The issue size of Senores Pharmaceuticals Ltd. IPO is ₹317.49 - 333.71 crore.
The Senores Pharmaceuticals Ltd. IPO opens for subscription on 2024-12-20 and closes on 2024-12-24.
The price range of Senores Pharmaceuticals Ltd. IPO is ₹372.00 to ₹391.00.
The lot size of Senores Pharmaceuticals Ltd. IPO is 38 shares.
The registrar of Senores Pharmaceuticals Ltd. IPO is MUFG Intime India Pvt Ltd..
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.